Carl Berke, PhD is a Partner at Mass General Brigham Ventures and has more than 25 years of experience in the practice and management of innovation to bring new technologies from lab to market. As a bench scientist and R&D director, he worked at Polaroid Corporation and Hygeia Sciences in the development of photographic and clinical products for both consumer and professional markets – he is an inventor on six U.S. patents. He served as a Partner at Integral/Analysis Group, a consulting firm focusing on the management of innovation and growth strategy for clients in healthcare and consumer products. He has been an active private equity investor as a member of Angel Healthcare Investors LLC and is a founder of Mass Medical Angels.
Carl currently holds board roles for InStride Health, Pykus Therapeutics and SeQure Dx. He is a also currently a Board observer for Rippl Care and Lyndra Therapeutics and previously held board roles at Annovation [anesthetic agent], Combinent [women’s health], InfoBionic [cardiac monitoring], Kasalis [robotics], LifeImage [diagnostic image sharing], QPID Health [bioinformatics], Quosa [research literature management software], Sebacia [dermatology therapy], Syntimmune [immunotherapy], and the Sudanese Education Fund [philanthropy].
Carl holds an A.B. degree from Cornell University and a PhD in Organic Chemistry from the University of California at Berkeley. He is also a Lecturer at the MIT Sloan School of Management, teaching various courses on the topic of biomedical enterprise.